Vandria SA bags CHF18m in Series A financing
Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2162 entries already.
Entries by Thomas Gabrielczyk
Cell-free protein synthesis systems
Cell-free protein synthesis (CFPS) systems allow rapid protein production in vitro without the need for living cells, offering distinct advantages.
Antabio SAS raises €25 m in Series B financing
Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.
Production process for cell-based coffee published
Scientists led by Heiko Rischer from the Finnish research centre VTT have published the proof of concept for cell-based coffee production.
Germany blocks deregulation of NGT breeds
At the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the adapted version of the EU Commission’s draft regulation on new genomic techniques.
Cathera SA closes Series B round at €42m
Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.
UK publishes £2bn vision for engineering biology
On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Valnevas Lyme vaccine trial completes recruitment
Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.
Takeover in ADC space: Abbvie snags ImmunoGen
AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.
AI protein specialist Cradle raises US$24m in Series A financing
Generative AI protein engineering specialist Cradle NV, has raised US$24m in a Series A financing round led by Index Ventures w